Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023
(Thomson Reuters ONE) -
GAITHERSBURG, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc.
(Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery,
development and commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced that it intends to offer, subject to market and other
conditions, $200 million aggregate principal amount of convertible senior
unsecured notes that will mature on February 1, 2023 (the Notes). The Notes will
be offered and sold only to qualified institutional buyers pursuant to Rule 144A
under the Securities Act of 1933, as amended. Novavax also expects to grant the
initial purchasers of the Notes an option to purchase up to an additional $30
million aggregate principal amount of the Notes, solely to cover over-
allotments.
Citigroup and J.P. Morgan are acting as joint book-running managers of the
offering.
"We completed five clinical trials during 2015, leading to the launch of two
Phase 3 trials and accelerating the pace to commercialization," said Stanley C.
Erck, President and CEO. "The purpose of this offering and the rationale for a
convertible note is to strengthen the balance sheet while minimizing dilution.
If completed, this offering will enhance our balance sheet as we engage
potential partners in discussions on RSV F Vaccine commercialization rights
outside North America and support our aggressive development and U.S.
commercialization plans."
While Novavax has not finalized its full financial results for the fiscal year
ended December 31, 2015, Novavax expects to report that it has approximately
$231 million of cash, cash equivalents and marketable securities as of December
31, 2015. This amount is preliminary, has not been audited and is subject to
change upon completion of the audit of Novavax' consolidated financial
statements as of and for the year ended December 31, 2015. Additional
information and disclosures would be required for a more complete understanding
of Novavax' financial position and results of operations as of December
31, 2015.
The Notes will bear cash interest, payable on February 1 and August 1 of each
year, beginning on August 1, 2016. The Notes will not be redeemable prior to
maturity. The Notes will be convertible into shares of Novavax common stock.
Final terms of the Notes, including interest rate, conversion rate, conversion
price, and certain other terms of the offering, will be determined at the time
of pricing.
Novavax intends to use the net proceeds from the offering for the advancement of
its clinical-stage vaccine candidates, including its recently initiated pivotal
Phase 3 clinical trials of its RSV F Vaccine in older adults and pregnant women,
as well as its other clinical and preclinical research programs, and general
corporate purposes, which may include working capital, product development,
manufacturing and process development expenditures, capital expenditures,
acquisitions and other strategic purposes. Novavax would also use a portion of
the net proceeds from the offering to pay the cost of certain capped call
transactions (described below).
In connection with the pricing of the Notes, Novavax intends to enter into
privately negotiated capped call transactions with one or more option
counterparties. The capped call transactions are expected generally to reduce
the potential dilution upon conversion of the Notes in the event that the market
price per share of Novavax' common stock, as measured under the terms of the
capped call transactions, is greater than the strike price of the capped call
transactions, which initially corresponds to the conversion price of the Notes
and is subject to anti-dilution adjustments similar to those applicable to the
conversion rate of the Notes. If, however, the market price per share of
Novavax' common stock, as measured under the terms of the capped call
transactions, exceeds the cap price of the capped call transactions, there would
nevertheless be dilution upon conversion of the Notes to the extent that such
market price exceeds the cap price of the capped call transactions. If the
initial purchasers of the Notes exercise their over-allotment option, Novavax
expects to enter into additional capped call transactions with the option
counterparties.
Novavax expects that, in connection with the capped call transactions, the
option counterparties or their respective affiliates will enter into various
hedging transactions, including (without limitation) derivative transactions,
with respect to Novavax' common stock and/or to purchase Novavax' common stock
concurrently with or shortly after the pricing of the Notes. This activity could
impact the market price of Novavax' common stock or the Notes at that time, and
could result in a higher effective conversion price for the Notes. In addition,
the option counterparties and/or their respective affiliates may, from time to
time, modify their hedge positions by entering into or unwinding various hedging
positions, including (without limitation) derivative transactions, with respect
to Novavax' common stock and/or by purchasing or selling Novavax' common stock
or other securities of Novavax in secondary market transactions. This activity
could also impact the market price of Novavax' common stock or the Notes, which
could affect the value of the shares that a holder of Notes receives upon
conversion of the Notes.
The offer and sale of the Notes are not being registered under the Securities
Act, or any state securities laws. The Notes may not be offered or sold in the
United States except pursuant to an exemption from the registration requirements
of the Securities Act and any applicable state securities laws.
This news release does not constitute an offer to sell or a solicitation of an
offer to buy the securities described herein, nor shall there be any sale of
these securities, in any state or jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the laws
of such jurisdiction.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to
delivering novel products to prevent a broad range of infectious diseases. Its
recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for groundbreaking innovation that improves global health through
safe and effective vaccines.
Forward-Looking Statements
This press release contains forward-looking statements. Investors are cautioned
not to place undue reliance on these forward-looking statements, including, but
not limited to,statements about Novavax' intention to commence an offering of
Notes and enter into capped call transactions, the expected terms of the
offering, the Notes and the capped call transactions, Novavax' anticipated use
of proceeds, Novavax' expectations with respect to the pace to
commercialization, Novavax' plans to engage in partnering discussions for its
RSV F Vaccine and Novavax' aggressive development and U.S. commercialization
plans. Each forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or implied
in such statement. Applicable risks and uncertainties include, but are not
limited to, those related to whether or not Novavax will be able to consummate
the offering and the capped call transactions on the timeline or with the terms
anticipated, if at all, the conduct, timing and potential results from Novavax'
clinical-trials and other preclinical studies, Novavax' plans for and potential
timing of regulatory filings, the expected timing and content of regulatory
actions, Novavax' plans regarding partnering activities and business development
initiatives, and the timing and success of Novavax' commercialization, if any,
of its product candidates. In addition, Novavax' management retains broad
discretion with respect to the allocation of the net proceeds of this offering.
Applicable risks also include those that are listed under the heading "Risk
Factors" and elsewhere in Novavax' Annual Report on Form 10-K for the fiscal
year ended December 31, 2014, in addition to the risk factors that are included
from time to time in Novavax' subsequent SEC filings. Novavax undertakes no
obligation to update these forward-looking statements to reflect events or
circumstances occurring after this press release. Except as otherwise noted,
these forward-looking statements speak only as of the date of this press
release. All forward-looking statements are qualified in their entirety by this
cautionary statement.
Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
ir(at)novavax.com
240-268-2000
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novavax, Inc. via GlobeNewswire
[HUG#1981011]
Unternehmensinformation / Kurzprofil:
Datum: 25.01.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 446231
Anzahl Zeichen: 10205
contact information:
Town:
Maryland
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 219 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023"
steht unter der journalistisch-redaktionellen Verantwortung von
Novavax, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
